NCT02528682View on ClinicalTrials.gov

MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Hematological Malignancies
Interventions
BIOLOGICAL

MiHA-loaded PD-L-silenced DC Vaccination

Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).

Trial Locations (1)

6500 HB

Trialoffice Haematology-Oncology, Nijmegen

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Dutch Cancer Society

OTHER

lead

Radboud University Medical Center

OTHER

NCT02528682 - MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT | Biotech Hunter | Biotech Hunter